Updated:
Yunnan Baiyao Group
Yunnan Baiyao Group was founded in 1993 to commercialize the legendary hemostatic powder invented by Qu Huanzhang in 1902. It is headquartered in Kunming and...
Yunnan Baiyao Group
Yunnan Baiyao Group was founded in 1993 to commercialize the legendary hemostatic powder invented by Qu Huanzhang in 1902. It is headquartered in Kunming and listed on the Shenzhen Stock Exchange, where it functions as a hybrid operating company and strategic corporate investor. Chairman Dong Ming and President Yin Pinyao oversee an entity that retains the original secret-formula franchise while expanding through targeted equity investments. The group allocates capital across three primary lines: the legacy pharmaceutical division anchored by the Yunnan Baiyao hemostatic products, a rapidly growing consumer health segment led by its toothpaste brand, and a strategic investment arm pursuing healthcare services and biotech. Confirmed investment areas include dental care chains, diagnostic platforms, and traditional Chinese medicine modernization, with a geographic concentration on China's domestic market. The firm uses direct equity acquisitions rather than fund commitments. Yunnan Baiyao Group employs thousands of staff with main operations in Kunming. In 2023, the firm invested approximately $1.5 billion in a Shanghai-based healthcare services platform to vertically integrate its distribution. Adjacent listed vehicles include Yunnan Baiyao Group Co., Ltd. on the Shenzhen exchange, with no disclosed philanthropic foundation or club memberships. What differentiates this corporate investor is its dual identity: an operating company sitting atop a trade-secret-protected product with century-old brand recognition, using its public-company currency and cash flows to acquire downstream healthcare assets. This is not a family office or a passive allocator — it is an industrial acquirer whose investment thesis is inseparable from its branded product franchise.
General information
Firm type
Corporate Investor
Year founded
1993
AUM
¥540 Bn
Location
Region
Asia
Country
China
City
Kunming
Corporate office
Kunming, Yunnan, China
Principals
Dong Ming
Chairman
Yin Pinyao
President
Sector focus
Frequently asked questions
Who runs investment decisions at Yunnan Baiyao Group?
Investment and strategic allocation decisions are directed by Chairman Dong Ming and President Yin Pinyao. There is no externally managed allocation committee structure. The group's investments are executed at the corporate level, reflecting the leadership's dual role as both operating executives and capital allocators.
Does Yunnan Baiyao Group invest from a separate fund or a family office structure?
No. Yunnan Baiyao Group is a publicly traded operating corporation listed on the Shenzhen Stock Exchange. Its investments are made directly from the corporate balance sheet, not from a dedicated investment fund or family office pool. The firm acts as a strategic acquirer rather than a financial investor.
What sectors does Yunnan Baiyao Group explicitly target for investment?
The group concentrates on pharmaceuticals, consumer health products, dental care, diagnostics, and traditional Chinese medicine modernization. It also pursues healthcare services platforms that offer vertical integration with its existing product distribution network. It does not invest in sectors unrelated to its healthcare franchise, such as technology or real estate development.
How does the firm source proprietary deal flow?
Yunnan Baiyao sources opportunities primarily through its deep industry relationships in China's healthcare sector and its state-owned heritage. As an operator with brand recognition across the country, it identifies acquisition targets that align with its existing distribution channels and therapeutic areas, rather than relying on competitive auction processes or third-party advisors.
Where does the underlying capital for Yunnan Baiyao's investments come from?
Investment capital derives from the operating cash flows of its pharmaceutical and consumer health businesses, supplemented by access to public equity markets through its Shenzhen Stock Exchange listing. The firm occasionally uses debt financing for larger acquisitions, but its core funding source is retained earnings from product sales.
How is Yunnan Baiyao Group related to its historical formula origins?
The corporation is the direct legal successor to the Yunnan Baiyao formulation invented in 1902. The exact composition of the hemostatic powder remains a state-protected trade secret in China, a status that underpins the brand's enduring moat. The investment strategy extends this legacy franchise into adjacent categories like toothpaste and wound care products.
Does Yunnan Baiyao Group participate in co-investments alongside external GPs?
The group does not typically engage in co-investments alongside external general partners in a traditional private equity model. Its posture is that of a direct, controlling or significant-minority acquirer in operating companies, integrated into its own corporate structure rather than held in passive minority pools.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: